Table 1.
Review of the literature in table format.
| Case | Age | Associated Findings | FIGO stage | Chemotherapy | Radiation | Recurrence | Follow-up time (mo) |
|---|---|---|---|---|---|---|---|
| 1–5 (McFarland et al., 2016) | 42–72 | Endometriosis in 3 of 5 | IA(3 cases), IB(1 case), IIIC(1case) | not reported | not known | N (IA, IB cases) Y (IIIC case) | 18 (IA, IB cases) 56 (IIIC case) |
| 6 (Chapel, 2018) | 80 | Serous borderline tumor and low-grade serous carcinoma | not reported | carboplatin paclitaxel | N | N | 3 |
| 7 (McCluggage et al., 2018) | 61 | Serous borderline tumor (low-grade serous carcinoma in extraovarian tissues) | IIIA1 | carboplatin paclitaxel | N | not reported | not reported |
| 8 (McCluggage et al., 2018) | 66 | Borderline endometrioid adenofibroma | not reported | not reported | not reported | not reported | not reported |
| 9 (McCluggage et al., 2018) | 77 | Endometriosis; mixed serous and mucinous cystadenoma | not reported | not reported | not reported | not reported | not reported |
| 10 (McCluggage et al., 2018) | 50 | None | not reported | not reported | not reported | not reported | not reported |
| 11 (McCluggage et al., 2018) | 73 | Serous cystadenoma | not reported | not reported | not reported | not reported | not reported |
| 12 (Dundr, 2020) | 61 | Serous borderline tumor | IV | carboplatin paclitaxel bevacizumab | N | N | 12 |
| 13 (present case) | 67 | Endometriosis | IA | carboplatin paclitaxel bevacizumab | N | Y | 18 |